|
|
Vaccine Detail
|
ALVAC gp100 Vaccine |
| Vaccine Information |
- Vaccine Name: ALVAC gp100 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: glycoprotein 100 (gp100) (NCT00610311; NCIT_C180518)
- gp100 (PMEL)
gene engineering:
- Type: Recombinant vector construction
- Description: This vaccine encodes for gp100. (NCIT_C180518; NCT00610311)
- Detailed Gene Information: Click Here.
- Immunization Route: subcutaneous injection
- Description: The vaccine is composed of the replication-defective plaque purified recombinant canarypox virus (ALVAC) that encodes the glycoprotein 100 (gp100) gene, with potential antineoplastic activity. The vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 melanoma antigen, resulting in decreased tumor growth. (NCIT_C180518) The vaccine can be used in combination with anti-gp100:154-162 T cell receptor (TCR) peripheral blood lymphocytes (PBL), interleukin-2 (IL-2), cyclophosphamide, fludarabine phosphate, and Aldesleukin. (NCT00610311)
|
| Host Response |
|
|
| References |
NCIT_C180518: ALVAC gp100 Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C180518]
NCT00610311: Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma [https://clinicaltrials.gov/study/NCT00610311]
|
|
